![Armin W. Mäder](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Armin W. Mäder
Oprichter bij Qvanteq AG
Profiel
Armin W.
Mäder is the founder and Chairman of Qvanteq AG, a company founded in 2009.
He is currently the Director at Neurotune AG.
Dr. Mäder has previously served as Chairman & Chief Executive Officer at Memo Therapeutics AG, Chief Operating Officer at AC Immune SA, and Chief Financial Officer at Institut Straumann AG.
He holds a graduate and doctorate degree from the Swiss Federal Institute of Technology and an MBA from the International Institute for Management Development.
Actieve functies van Armin W. Mäder
Bedrijven | Functie | Begin |
---|---|---|
Neurotune AG
![]() Neurotune AG Pharmaceuticals: MajorHealth Technology Neurotune AG develops medications for neuropathic pain and sarcopenia. The firm is developing treatments which modulate the connections between nerve cells and its target cells. The company was founded by Bruno Oesch in January 2005 and is headquartered in Schlieren-Zurich, Switzerland. | Directeur/Bestuurslid | - |
Qvanteq AG
![]() Qvanteq AG BiotechnologyHealth Technology Qvanteq AG develops novel bioactive stents to address and overcome the clinical adverse. Its products include technology, intracranial stents, Qstent Periphry, and Qstent Coronary. The company was founded in 2009 and is headquartered in Zurich, Switzerland. | Oprichter | 01-01-2009 |
Eerdere bekende functies van Armin W. Mäder
Bedrijven | Functie | Einde |
---|---|---|
AC IMMUNE SA | Operationeel Directeur | - |
Memo Therapeutics AG
![]() Memo Therapeutics AG BiotechnologyHealth Technology Memo Therapeutics AG develops recombinant immunoglobulins and human-derived monoclonal antibodies. Its products include human antibodies, human immune repertoire analysis, classic antibody discovery and pipeline. The company was founded by Christoph Esslinger on November 29, 2012 and is headquartered in Basel, Switzerland. | Algemeen Directeur | - |
Institut Straumann AG
![]() Institut Straumann AG Medical/Nursing ServicesHealth Services Institut Straumann AG operates a dentistry group. It engages in the research, development and manufacturing dental implants, instruments, prosthetics and tissue regeneration products for use in tooth replacement and restoration solutions. The company is headquartered in Basel, Switzerland. | Financieel Directeur/CFO | - |
Opleiding van Armin W. Mäder
International Institute for Management Development | Masters Business Admin |
Swiss Federal Institute of Technology | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
AC IMMUNE SA | Health Technology |
Bedrijven in privébezit | 4 |
---|---|
Neurotune AG
![]() Neurotune AG Pharmaceuticals: MajorHealth Technology Neurotune AG develops medications for neuropathic pain and sarcopenia. The firm is developing treatments which modulate the connections between nerve cells and its target cells. The company was founded by Bruno Oesch in January 2005 and is headquartered in Schlieren-Zurich, Switzerland. | Health Technology |
Institut Straumann AG
![]() Institut Straumann AG Medical/Nursing ServicesHealth Services Institut Straumann AG operates a dentistry group. It engages in the research, development and manufacturing dental implants, instruments, prosthetics and tissue regeneration products for use in tooth replacement and restoration solutions. The company is headquartered in Basel, Switzerland. | Health Services |
Memo Therapeutics AG
![]() Memo Therapeutics AG BiotechnologyHealth Technology Memo Therapeutics AG develops recombinant immunoglobulins and human-derived monoclonal antibodies. Its products include human antibodies, human immune repertoire analysis, classic antibody discovery and pipeline. The company was founded by Christoph Esslinger on November 29, 2012 and is headquartered in Basel, Switzerland. | Health Technology |
Qvanteq AG
![]() Qvanteq AG BiotechnologyHealth Technology Qvanteq AG develops novel bioactive stents to address and overcome the clinical adverse. Its products include technology, intracranial stents, Qstent Periphry, and Qstent Coronary. The company was founded in 2009 and is headquartered in Zurich, Switzerland. | Health Technology |